In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Teva buys Copley for $220mm in cash

Executive Summary

Israel's largest pharmaceutical company, Teva Pharmaceutical, is buying US generics company Copley for $220mm, paying $11 a share, a (pr)16.8% premium. Hoechst, which owns 52% of Copley, has agreed to sell its stake. Copley had sales last year of $133.5mm, and its net income was just over $10mm.
Deal Industry
  • Pharmaceuticals
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash

Related Companies